HPN-217 is a B cell maturation antigen (BCMA)-targeting Tri-specific
T cell Activating Construct (TriTAC®).
HPN-217 is being developed by Harpoon Therapeutics through Phase 1/2 clinical trials. AbbVie has an option to license worldwide exclusive rights to HPN-217 after completion of the Phase 1/2 trial. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities.
Type of MoleculeBiologic
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted, Approved)|
|Multiple Myeloma in Relapse||n/a||